Editas Medicine (EDIT) Stock: Buy, Sell, or Hold?
EDIT - Editas Medicine, Inc. Common Stock
$2.58
0.16 (6.61%)
▲
5d:
+5.52%
30d:
-8.83%
90d:
-7.19%
BUY
HIGH Confidence
Analysis Updated: Oct 20, 2026 12:00 AM ET
Earnings: Nov 09, 2026
19d
Get Alerted When EDIT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EDIT shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: EDIT shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: EDIT is currently trading at $2.58, which is considered fair relative to its 30-day fair value range of $2.48 to $2.80.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.25, while resistance sits at $2.97. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: EDIT scores 78/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.10 (+152.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.25, while resistance sits at $2.97. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: EDIT scores 78/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.10 (+152.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.48 -
$2.80
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (78/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.6%)
- BULLISH: Trading 152.1% below Wall St target ($6.10)
- BULLISH: Bottoming setup score 78/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$2.48 -
$2.80
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.25
Resistance Level
$2.97
Current Trend
Strong Uptrend
Technical data as of
Oct 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.21
Wall Street Target
$6.10
(+152.1%)
Revenue Growth (YoY)
232.3%
Profit Margin
-157.3%
Share & Embed Analysis
Last updated: October 20, 2026 4:33 PM ET
Data refreshes hourly during market hours. Next update: 5:33 PM
Data refreshes hourly during market hours. Next update: 5:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDIT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 66 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 67 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 73 BUY |
